Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.
Toronto, Canada. In Acs Med Chem Lett, 13 Dec 2014
Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 domain complexation events in vitro, silences activated STAT5 in leukemic cells, as well as STAT5's downstream transcriptional targets, including MYC and MCL1, and, as a result, leads to apoptosis.
Role of miR-15/16 in CLL.
Columbus, United States. In Cell Death Differ, Jul 2014
miR-15/16 cluster targets multiple oncogenes, including BCL2, Cyclin D1, MCL1 and others.
Anti-apoptotic BCL-2 family proteins in acute neural injury.
Dublin, Ireland. In Front Cell Neurosci, Dec 2013
We discuss overlapping and differential effects of the individual family members BCL-2, BCL-extra long (BCL-XL), myeloid cell leukemia 1 (MCL-1), and BCL2-like 2 (BCL-W) in the control of survival during development and pathophysiological processes such as trophic factor withdrawal, ischemic injury, excitotoxicity, oxidative stress and energy stress.
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Milano, Italy. In Immunol Lett, Sep 2013
The BCL2 family members play a central role in regulating programmed cell death (apoptosis) and arbitrating the cellular fate through an accurate balance between pro-apoptotic (BAX, BAK, and BH3-only proteins) and pro-survival (BCL2 and its closest homologues, BCLXL, BCLW and MCL-1) factors.
BH3 mimetics: status of the field and new developments.
More papers using
Paris, France. In Mol Cancer Ther, Sep 2013
The prototype BH3 mimetic ABT-737 selectively targets the three prosurvival proteins BCL-XL, BCL-2, and BCL-W (but not MCL-1 or A1) and its oral derivative ABT-263 has proved promising in clinical trials.